Interferon Drugs Market is Segmented By Types (Interferon Alpha, Interferon Beta, Interferon Gamma), By Application(Hepatitis C, Hepatitis B, Leukemia, Melanoma, Multiple Sclerosis, Renal Cell Carcinoma), By Route of Administration(Intravenous, Subcutaneous. Intramuscular), By Distribution Channel(Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Interferon Drugs Market Overview
Interferon Drugs Market is expected to reach at a CAGR of 4.0% during the forecast period (2024-2031).
Interferons are a type of protein that the immune system (white blood cells, fibroblasts, or T-cells) produces in response to viral infections, bacteria, tumor cells, and other pathogens. These glycoproteins are also known as cytokines, and they are frequently referred to as first-line defenders against microbial infections. These proteins fight infections by inducing an immune response, which results in the production of immunologic cells such as natural killer cells, macrophages, and T cells. Interferons are a cutting-edge and effective treatment for various chronic disorders, including cancer, hepatitis, multiple sclerosis, and others. Interferons do not destroy cancer cells directly; instead, they inhibit their growth, increasing the immune system's response in the process. Interferons are divided into type 1 interferon and type 2 interferon, produced by white blood cells and fibroblasts, respectively. T-cells create type 2 interferon, which is gamma interferon. Interferons are generated in vast quantities and utilized as medications to treat various chronic conditions thanks to recombinant DNA technology.
Interferon Drugs Market Scope and Summary
|
Metrics |
Details |
|
Market CAGR |
4.0% |
|
Segments Covered |
By Type, By Application, By Route of Administration, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Interferon Drugs Market Dynamics
The global interferon drugs market is being driven by an increase in chronic diseases such as hepatitis B and C, cancer, multiple sclerosis, and others. Over 15 human interferons are currently available on the market, with the number expected to rise in the coming years. Other factors that are the growth of the global interferon drugs market include increased R&D investments, increased funding, and technological advancements..
The increase in prevalance of chronic diseases in the market will drive the market growth
Rising instances of chronic diseases such as hepatitis C and B ,multiple sclerosis, cancer, and leukemia etc are expected to increase the global market demand for interferon drugs. Leading players are increasing their R&D activities to develop and introduce technologically advanced drugs. By 2021, the American Cancer Society projects the following numbers for multiple myeloma in the United States: A total of 34,920 additional cases will be identified (19,320 in men and 15,600 in women).
An increase in the global geriatric population are expected to drive market expansion. The world's senior population is rapidly increasing, with people aged 60 and up accounting for more than 10% of the population, a figure that is anticipated to rise to more than 20% by 2050. Compared to younger persons, the elderly population is more susceptible to infectious diseases. A range of infectious disorders afflicts the elderly, which compromise the host's response to infection. As a result, the need for infectious disease diagnostics among the elderly increases. The increasing development of the older population is predicted to increase the number of interferon drugs, boosting global demand during the forecast period.
High cost of R&D is likely to hamper the market growth
The development of interferons is expensive in terms of research and development. Interferon development is more expensive than chemically manufactured small molecules, has higher operating costs, and necessitates a larger capital commitment. Biological medications are more complicated than small molecules and require more complicated manufacturing procedures. Additionally, for successful registration, producers must submit more data to establish the efficacy and safety of these biologics in pre-clinical and clinical studies. As a result, biologics registration is a costly and time-consuming process, limiting market expansion. The marketed pharmaceuticals would be priced far more than the actual manufacturing costs due to hefty R&D expenses and a lengthy testing and manufacturing procedure, and this factor is likely to hamper market expansion.The patent expiration of interferon drugs is also significant market restraint. Interferon drugs are costly, making them unaffordable for patients. High drug prices are a major source of concern, limiting patients' access to medications. Certain advanced treatments are not covered by the government in developing economies, making interferon treatment less accessible to the patient population. These factors are impeding the global interferon drug market's growth.
COVID-19 Impact Analysis
The market for interferons is predicted to rise as a result of the coronavirus pandemic. This is due to ongoing clinical trials of numerous medication candidates, including interferons, as potential COVID-19 therapy alternatives. Interferon-beta (IFN-beta) is a naturally occurring protein that regulates antiviral responses in the body. The Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Research Authority (HRA) have given their approval to start interferon trials. For example, SNG001 is an interferon-beta-1a inhalation formulation given directly to the lungs by nebulization.
Interferon Drugs Market Segment Analysis
The multiple sclerosis segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Multiple sclerosis is a neurological disease that primarily affects adults between 20 and 50. According to the Multiple Sclerosis Foundation, 2.5 million people were affected by this autoimmune disease in 2017, with an annual global incidence of roughly 7 cases per 100,000 people. According to the study, prevalence rates range from 50 to 120 persons per 100,000, depending on ethnicity and geographic latitude. Furthermore, according to the Multiple Sclerosis Foundation, an estimated 400,000 people in the United States suffer from the condition, with roughly 200 new cases identified each week.
Multiple sclerosis comes second after congestive heart failure in terms of direct and indirect health care costs, with costs ranging from US$ 8,528 to US$ 54,244 per patient per year, according to a poll by Healthline Media. As a result, the rising prevalence of multiple sclerosis is a crucial element propelling the global interferon medicines market.
Interferon Drugs Market Geographical Analysis
North America region holds the largest market share of global interferon drugs market
North America dominated the interferon medicines market (percentage) in 2019, and the region is expected to maintain its dominance over the forecast period of 2021 to 2028. The US government's approval of several types of IFN is boosting regional market value. Major manufacturers' ongoing attempts to produce advanced medication for the effective treatment of ailments also add to the regional market's dominance.
The American Cancer Society's leukemia projections for the United States in 2022 are as follows:There were around 60,650 new cases of leukemia (all types) and 24,000 fatalities due to leukemia (all kinds). A total of 20,050 new cases of acute myeloid leukemia have been reported (AML). The majority will be in their adult years.
AML is responsible for around 11,540 fatalities. Almost everyone will be an adult. Multiple myeloma is a rather uncommon malignancy. The lifetime risk of developing multiple myeloma in the United States is 1 in 132. (0.76 percent ). By 2021, the American Cancer Society projects the following numbers for multiple myeloma in the United States: A total of 34,920 additional cases will be identified (19,320 in men and 15,600 in women).
Furthermore, increased R&D investment by government organizations and pharmaceutical companies for diseases detection and treatment, such as chronic ailments, is one of the primary drivers boosting the interferon drugs market in the country.
However, Asia-Pacific is assessed to grow the fastest during the forecast period, owing to increased healthcare spending and increased awareness about the treatment options available. Other factors that contribute to the market's growth include a large patient base of various chronic diseases such as leukemia and multiple sclerosis, which necessitate the use of interferons, which contribute to the growth of the Asia-Pacific interferon drugs market.
Interferon Drugs Market Competitive Landscape
The interferon drugs market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Merck and Co., Novartis, Bayer, Biogen ,Roche ,Biosidus, Zydus Cadila, Amega Biotech, Rhein-Minapharm ,Probiomed, 3 Sbio, Apple Pharmaceuticals, Mili Healthcare, A S Biotech, Pfizer Inc, Hoffmann-La Roche Ltd.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood and blood products market globally. For instance Bayer and Curadev Pvt. Ltd., an Indian drug discovery company, have announced a research collaboration and license agreement for Curadev's STING antagonist program. Bayer and Curadev's collaboration aims to find new drug candidates for the treatment of lung diseases, cardiovascular diseases, and other inflammatory diseases. Because STING is known to activate the innate immune system in auto-inflammatory diseases, STING antagonists have enormous potential for new treatments.
Key Developments
In January 2021, Synairgen plc announced a clinical trial agreement to include its inhaled interferon beta-1a treatment (SNG001) in the ACTIV-2/A5401 Phase II/III trial in patients with COVID-19 who do not yet require hospitalization. The trial is funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).
Faron Pharmaceuticals, a clinical-stage biopharmaceutical company, announced in 2021 that the US FDA approved the phase 2 and 3 'HIBISCUS' trial evaluating its intravenous IFN beta-1a 'Traumakine' for the treatment of hospitalized patients with Covid-19. According to the company, Traumakine would be used before the current practice of corticosteroids to prevent systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS), improve the clinical condition, and reduce patient death, based on the study.
The European Commission (EC) has ratified a new intramuscular (IM) injection route for Biogen's Plegridy, specifically for the treatment of relapsing-remitting multiple sclerosis (RRMS) (RRMS). Plegridy (peginterferon beta-1a) is also a long-acting RRMS treatment. The new route of administration provides patients with the same efficacy and safety as SC administration, and it can reduce injection site reactions.
Pfizer Inc
Overview: Pfizer Inc. is a global biopharmaceutical corporation founded on research. Biopharmaceutical products are discovered, developed, manufactured, marketed, sold, and distributed. Medicines and vaccines are part of the company's global portfolio. The company develops health, prevention, treatments, and cures across markets. To support and offer access to healthcare, it collaborates with healthcare providers, governments, and local communities. Its medications and vaccines benefit healthcare providers and patients by treating diseases and improving health and wellness. Wholesalers, retailers, hospitals, clinics, government agencies, and pharmacies customers for their prescription pharmaceutical items.
Product Portfolio:
Rebif Rebidose: REBIF (interferon beta-1a) is a 166-amino-acid glycoprotein with a molecular weight of 22,500 daltons that has been purified. It's made via recombinant DNA technology, which involves genetically engineering Chinese Hamster Ovary cells and inserting the human interferon-beta gene into them. REBIF has the same amino acid sequence as natural fibroblast-derived human interferon beta. Natural interferon beta and interferon beta-1a (REBIF) are both glycosylated, with a single N-linked complex carbohydrate moiety in each.Multiple sclerosis is treated using this drug (MS). Although interferon is not a cure for MS, it may help to delay disease progression and reduce symptom flare-ups (such as balance problems, numbness, or weakness).
